Greenwich LifeSciences, Inc. (GLSI) 10-Year Financial Performance & Capital Metrics

GLSI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutGreenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Show more

Revenue $0
EBITDA -$16M -71.7%
Net Income -$16M -77.6%
EPS (Diluted) -1.21 -75.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -341.95% -282.9%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Expensive at 150.4x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-85.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM-82.5%

ROCE

10Y Avg-102.34%

5Y Avg-102.34%

3Y Avg-160.21%

Latest-346.78%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.55B	7.62	54.43	55.85%	3.98%	15.63%	0.35%	1.02
EXELExelixis, Inc.	12.13B	45.23	25.70	18.49%	29.63%	31.37%	5.23%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.93	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.16B	6.31	-2.99		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.4B	8.07	-3.42	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.1B	11.25	-6.15			-33.24%		0.01
ZLABZai Lab Limited	2.17B	19.61	-7.54	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.67B	12.39	-10.41	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-3.61K	-3.61K	-3.61K	-3.61K	-3.61K	-3.61K	-3.61K	-3.61K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	0%	-0%	-0%	0%	0%	0%
Operating Expenses+	1.57M	1.69M	3.43M	1.86M	4.6M	8.04M	9.33M	16.01M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	346.81K	419.64K	818.89K	806.19K	1.04M	1.56M	1.63M	3.06M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	1.22M	1.27M	2.61M	1.06M	3.56M	6.48M	7.7M	12.95M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-1.57M	-1.69M	-3.43M	-1.86M	-4.6M	-8.04M	-9.33M	-16.01M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.07%	-1.03%	0.46%	-1.47%	-0.75%	-0.16%	-0.72%
EBITDA+	-1.57M	-1.69M	-3.42M	-1.86M	-4.59M	-8.04M	-9.32M	-16.01M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.07%	-1.03%	0.46%	-1.47%	-0.75%	-0.16%	-0.72%
D&A (Non-Cash Add-back)	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K
EBIT	-1.57M	-1.69M	-3.43M	-1.86M	-4.6M	-8.04M	-9.33M	-15.79M
Net Interest Income+	0	0	0	832	27.37K	215.02K	436.06K	223.01K
Interest Income	0	0	0	832	27.37K	215.02K	436.06K	223.01K
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	0	0	0	832	27.37K	215.02K	436.06K	223.01K
Pretax Income+	-1.57M	-1.69M	-3.43M	-1.86M	-4.57M	-7.83M	-8.89M	-15.79M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	3	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.57M	-1.69M	-3.43M	-1.86M	-4.57M	-7.83M	-8.89M	-15.79M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.07%	-1.03%	0.46%	-1.45%	-0.71%	-0.14%	-0.78%
Net Income (Continuing)	-1.57M	-1.69M	-3.43M	-1.86M	-4.57M	-7.83M	-8.89M	-15.79M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.13	-0.14	-0.29	-0.15	-0.35	-0.61	-0.69	-1.21
EPS Growth %	-	-0.08%	-1.07%	0.48%	-1.33%	-0.74%	-0.13%	-0.75%
EPS (Basic)	-0.13	-0.14	-0.29	-0.15	-0.35	-0.61	-0.69	-1.21
Diluted Shares Outstanding	11.74M	11.97M	11.74M	12.7M	12.94M	12.91M	12.85M	13.01M
Basic Shares Outstanding	11.74M	11.97M	11.74M	12.7M	12.94M	12.91M	12.85M	13.01M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	54	85.1K	6.83K	28.66M	27.2M	13.47M	6.99M	4.09M
Cash & Short-Term Investments	54	85.1K	6.83K	28.66M	27.2M	13.47M	6.99M	4.09M
Cash Only	54	85.1K	6.83K	28.66M	27.2M	13.47M	6.99M	4.09M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0
Total Non-Current Assets+	27.05K	23.44K	19.84K	16.23K	12.62K	9K	5.39K	1.78K
Property, Plant & Equipment	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	23.44K	19.84K	16.23K	12.62K	9K	5.39K	1.78K
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	27.1K	108.55K	26.67K	28.68M	27.22M	13.48M	6.99M	4.09M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	3%	-0.75%	1074.2%	-0.05%	-0.5%	-0.48%	-0.41%
Total Current Liabilities+	557.5K	728.6K	1.38M	1.05M	385.17K	262.9K	294.41K	1.56M
Accounts Payable	161.15K	277.56K	730.31K	710.97K	0	0	35.47K	1.18M
Days Payables Outstanding	16.31K	28.09K	73.9K	71.9K	-	-	3.58K	118.99K
Short-Term Debt	0	0	635.15K	275.15K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	396.36K	451.04K	0	0	0	0	0	382.2K
Current Ratio	0.00x	0.12x	0.00x	27.41x	70.63x	51.23x	23.74x	2.62x
Quick Ratio	0.00x	0.12x	0.00x	27.41x	70.63x	51.23x	23.74x	2.62x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	8M	9.5M	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	8M	9.5M	0	0	0	0	0	0
Total Liabilities	8.56M	10.23M	1.38M	1.05M	385.17K	262.9K	294.41K	1.56M
Total Debt+	0	0	635.15K	275.15K	0	0	0	0
Net Debt	-54	-85.1K	628.32K	-28.39M	-27.2M	-13.47M	-6.99M	-4.09M
Debt / Equity	-	-	-	0.01x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-8.53M	-10.12M	-1.35M	27.63M	26.83M	13.21M	6.7M	2.53M
Equity Growth %	-	-0.19%	0.87%	21.46%	-0.03%	-0.51%	-0.49%	-0.62%
Book Value per Share	-0.73	-0.85	-0.11	2.18	2.07	1.02	0.52	0.19
Total Shareholders' Equity	-8.53M	-10.12M	-1.35M	27.63M	26.83M	13.21M	6.7M	2.53M
Common Stock	542	542	8.46K	12.7K	13.15K	12.85K	12.85K	13.15K
Retained Earnings	-22.1M	-23.79M	-27.21M	-29.08M	-33.65M	-41.47M	-50.36M	-66.15M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-541	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-120.85K	-114.95K	-293.27K	-1.15M	-4.29M	-6.2M	-6.48M	-7.27M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.05%	-1.55%	-2.93%	-2.72%	-0.44%	-0.04%	-0.12%
Net Income	-1.57M	-1.69M	-3.43M	-1.86M	-4.57M	-7.83M	-8.89M	-15.79M
Depreciation & Amortization	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K	3.61K
Stock-Based Compensation	0	0	194.94K	677.99K	660.58K	1.74M	2.38M	7.25M
Deferred Taxes	0	0	0	-777.76K	-1.19M	-1.75M	0	0
Other Non-Cash Items	-137.7K	-73.75K	0	777.76K	1.19M	1.75M	0	0
Working Capital Changes	1.45M	1.57M	2.93M	28.4K	-385.17K	-122.27K	31.5K	1.27M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	144.91K	80.97K	393.4K	-92.55K	-526.73K	0	35.47K	921.22K
Cash from Investing+	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	-129.84K	200K	215K	29.81M	2.84M	-7.54M	0	4.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	-129.84K	100K	215K	0	-275.15K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-120.85K	-114.95K	-293.27K	-1.15M	-4.29M	-6.2M	-6.48M	-7.27M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.05%	-1.55%	-2.93%	-2.72%	-0.44%	-0.04%	-0.12%
FCF per Share	-0.01	-0.01	-0.02	-0.09	-0.33	-0.48	-0.50	-0.56
FCF Conversion (FCF/Net Income)	0.08x	0.07x	0.09x	0.62x	0.94x	0.79x	0.73x	0.46x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-14.17%	-16.78%	-39.08%	-89.3%	-341.95%
Debt / Equity	-	-	-	0.01x	-	-	-	-
FCF Conversion	0.08x	0.07x	0.09x	0.62x	0.94x	0.79x	0.73x	0.46x

Frequently Asked Questions

Growth & Financials

Greenwich LifeSciences, Inc. (GLSI) grew revenue by 0.0% over the past year. Growth has been modest.

Greenwich LifeSciences, Inc. (GLSI) reported a net loss of $19.5M for fiscal year 2024.

Dividend & Returns

Greenwich LifeSciences, Inc. (GLSI) has a return on equity (ROE) of -342.0%. Negative ROE indicates the company is unprofitable.

Greenwich LifeSciences, Inc. (GLSI) had negative free cash flow of $8.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener